{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390583026740333312.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.11553/antibiotics.67.1_33"}},{"identifier":{"@type":"NDL_BIB_ID","@value":"025299503"}},{"identifier":{"@type":"URI","@value":"http://id.ndl.go.jp/bib/025299503"}},{"identifier":{"@type":"URI","@value":"https://ndlsearch.ndl.go.jp/books/R000000004-I025299503"}},{"identifier":{"@type":"NAID","@value":"40019994249"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2014221030"}}],"dc:title":[{"@language":"en","@value":"Prediction of clinical bacteriological efficacy of oral antibiotics using a mechanism-based pharmacokinetic-pharmacodynamics modeling"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"<p>The objective of this study was to predict the clinical bacteriological efficacy of antibiotics and to examine the pharmacodynamics (PD) characteristics of antibiotics against bacterial strains using a mechanism-based pharmacokinetic pharmacodynamics (PK-PD) modeling developed on the basis of interaction between drug concentrations and antibacterial activities.</p><p>Dynamic PD parameters (<i>ε</i>, <i>γ</i>, EC<sub>50</sub>) and growth rate of organisms (λ) were obtained from <i>in vitro</i> time-kill profile data of oral antibiotics, tebipenem pivoxil (TBPM-PI) and cefditoren pivoxil (CDTR-PI) against <i>Streptococcus pneumoniae</i> or <i>Haemophilus influenze</i>. PD characteristics of both drugs against <i>S. pneumoniae</i> or <i>H. influenzae</i> were examined, which indicated TBPM was concentration dependent as well as time-dependent, and CDTR was mainly time-dependent to exhibit their bactericidal activities. Next, we simulated TBPM and CDTR concentrations in plasma after oral administration according to the dosage regimen of each drug specified in package insert, using population pharmacokinetic parameters of both drugs in pediatric patients with infections. In addition, changes in viable in vivo bacterial counts in humans were simulated using dynamic PD parameters and mean plasma concentrations of each drug. As a result, simulated profile of viable counts of <i>S. pneumoniae</i> and <i>H. influenzae</i> were well corresponding to the bacteriological efficacy results in clinical double-blinded comparative study of TBPM-PI and CDTR-PI in oral administration to pediatric patients with acute otitis media.</p><p>As mentioned in the above, it was considered to be possible to clarify the PD characteristics of TBPM and CDTR against each bacterial strain using the mechanism-based PK-PD model developed on the basis of interaction between drug concentrations and antibacterial activities, and to estimate the clinical bacteriological efficacy of those drugs.</p>"}],"abstractLicenseFlag":"allow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410583026740333312","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000242736000"}],"foaf:name":[{"@language":"en","@value":"MATSUMOTO KAYOKO"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd."}]},{"@id":"https://cir.nii.ac.jp/crid/1410583026740333315","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000242736001"}],"foaf:name":[{"@language":"en","@value":"SUGANO TOSHIE"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd."}]},{"@id":"https://cir.nii.ac.jp/crid/1410583026740333314","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000242736002"}],"foaf:name":[{"@language":"en","@value":"SATO NOBUO"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd."}]},{"@id":"https://cir.nii.ac.jp/crid/1410583026740333313","@type":"Researcher","foaf:name":[{"@language":"en","@value":"IDA TAKASHI"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd."}]},{"@id":"https://cir.nii.ac.jp/crid/1410583026740333316","@type":"Researcher","foaf:name":[{"@language":"en","@value":"SHIBASAKI SHIGEKI"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03682781"},{"@type":"LISSN","@value":"03682781"},{"@type":"EISSN","@value":"21865477"},{"@type":"NDL_BIB_ID","@value":"000000000264"},{"@type":"ISSN","@value":"03682781"},{"@type":"NCID","@value":"AN00002626"}],"prism:publicationName":[{"@language":"en","@value":"The Japanese Journal of Antibiotics"},{"@language":"ja","@value":"The Japanese Journal of Antibiotics"},{"@language":"en","@value":"JJA"},{"@language":"en","@value":"Jpn J Antibiot."},{"@language":"en","@value":"Jpn. J. Antibiotics"},{"@language":"ja","@value":"Jpn. J. Antibiotics"},{"@language":"ja","@value":"JJA"}],"dc:publisher":[{"@language":"en","@value":"Japan Antibiotics Research Association"},{"@language":"ja","@value":"公益財団法人 日本感染症医薬品協会"}],"prism:publicationDate":"2014-02-25","prism:volume":"67","prism:number":"1","prism:startingPage":"33","prism:endingPage":"47"},"url":[{"@id":"http://id.ndl.go.jp/bib/025299503"},{"@id":"https://ndlsearch.ndl.go.jp/books/R000000004-I025299503"},{"@id":"https://search.jamas.or.jp/link/ui/2014221030"}],"availableAt":"2014-02-25","dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:2013363840"},{"@type":"NDL_SEARCH","@value":"oai:ndlsearch.ndl.go.jp:R000000004-I025299503"},{"@type":"CIA","@value":"40019994249"}]}